Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo takes on advanced cancers in early trial

NCT ID NCT05544929

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new drug called KFA115, either by itself or combined with the immunotherapy Keytruda (pembrolizumab), in 126 people with advanced cancers like lung, skin, kidney, and others. The main goal is to check safety and find the best dose. It is not yet known if the drug works against the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

KFA115 (an immunomodulatory drug) and pembrolizumab (Keytruda, an immunotherapy)

What this could lead to

If successful, this could point toward a new treatment option for several advanced cancers that have stopped responding to standard therapies.

What could go wrong

This is a very early Phase 1 trial focused on safety and dosing, not on effectiveness. It is small (126 people) and includes many cancer types, so results may not apply broadly. Side effects are unknown.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anal carcinoma anus neoplasm Carcinoma, Ovarian Epithelial clear cell adenocarcinoma colonic neoplasm colorectal adenocarcinoma colorectal cancer colorectal carcinoma colorectal neoplasm cutaneous melanoma Esophageal Neoplasms gastroesophageal cancer Head and Neck Neoplasms head and neck squamous cell carcinoma intestinal cancer kidney cancer lung neoplasm melanoma mesothelioma nasopharyngeal carcinoma nasopharyngeal neoplasm neoplasm non-small cell lung carcinoma ovarian cancer ovarian carcinoma ovarian epithelial tumor rectal neoplasm renal cell adenocarcinoma renal cell carcinoma skin neoplasm Squamous Cell Carcinoma of Head and Neck thymic carcinoma thymoma Thymus Neoplasms triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANAL CANCER CARCINOMA, NON-SMALL-CELL LUNG CARCINOMA, OVARIAN EPITHELIAL CARCINOMA, RENAL CELL CARCINOMA, THYMIC CUTANEOUS MELANOMA ESOPHAGOGASTRIC CANCER HIGH MICROSATELLITE INSTABILITY COLORECTAL CARCINOMA MESOTHELIOMA NASOPHARYNGEAL CARCINOMA SQUAMOUS CELL CARCINOMA OF HEAD AND NECK TRIPLE NEGATIVE BREAST NEOPLASMS

Contacts and locations

Locations

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Massachusetts General Hospital .

    Boston, Massachusetts, 02114, United States

  • NYU School of Medicine

    New York, New York, 10015, United States

  • Novartis Investigative Site

    Toronto, Ontario, M5G 2M9, Canada

  • Novartis Investigative Site

    Guangzhou, Guangdong, 510080, China

  • Novartis Investigative Site

    Beijing, 100036, China

  • Novartis Investigative Site

    Lyon, 69373, France

  • Novartis Investigative Site

    Dresden, Saxony, 01307, Germany

  • Novartis Investigative Site

    Essen, 45147, Germany

  • Novartis Investigative Site

    Hong Kong, 999077, Hong Kong

  • Novartis Investigative Site

    Milan, MI, 20133, Italy

  • Novartis Investigative Site

    Modena, MO, 41124, Italy

  • Novartis Investigative Site

    Chuo Ku, Tokyo, 104 0045, Japan

  • Novartis Investigative Site

    Singapore, 119074, Singapore

  • Novartis Investigative Site

    Seoul, 03080, South Korea

  • Novartis Investigative Site

    Barcelona, Catalonia, 08035, Spain

  • Novartis Investigative Site

    Taipei, 10002, Taiwan

  • SCRI Oncology Partners

    Nashville, Tennessee, 37203, United States

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, 15232, United States